Celularity Inc (CELU): Cash & Equivalents
$6.17M
As of 2025-12-31
$586.0K
As of 2026-06-30
-23.8%
3-year compound annual growth
-35.3%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.17M | +736.7% | 2026-04-30, Balance as of period end |
| 2024-12-31 | $738.0K | +225.1% | 2026-04-30, Balance as of period end |
| 2023-12-31 | $227.0K | -98.4% | 2025-05-08, Balance as of period end |
| 2022-12-31 | $13.97M | -62.5% | 2024-07-30, Balance as of period end |
| 2021-12-31 | $37.24M | -31.4% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $54.31M | n/m | 2022-03-31, Balance as of period end |
| 2019-12-31 | $917.0K | n/m | 2021-05-24, Balance as of period end |
| 2018-12-31 | $24.7K | n/a | 2020-03-24, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Celularity Inc (CELU) | 2025-12-31 | $6.17M | +736.7% |
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $27.14M | +20.8% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $90.39M | -10.7% |
| Alumis Inc. (ALMS) | 2025-12-31 | $89.67M | -47.1% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $80.88M | +45.8% |
| Verastem, Inc. (VSTM) | 2025-12-31 | $204.99M | +130.8% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $490.00M | -36.5% |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $9.02M | +28.4% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $5.63M | -58.2% |
Compare CELU, CUE, TRDA, ALMS side by side · Screen every company in Pharmaceutical Preparations ↗